Nautilus Biotechnology (NAUT) EBITDA (2020 - 2025)

Nautilus Biotechnology has disclosed EBITDA across 6 years of filings, most recently posting -$16.5 million for Q1 2025.

• EBITDA for Q1 2025 came in at -$16.5 million, up 14.25% year-over-year; the trailing twelve-month figure through Mar 2025 was -$68.5 million (down 1.94% YoY), and the FY2021 annual result was -$50.5 million, down 223.25% from the prior year.
• EBITDA came in at -$16.5 million for Q1 2025 at Nautilus Biotechnology, up from -$19.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.4 million in Q1 2021 to a low of -$19.2 million in Q1 2024.
• The 5-year median for EBITDA is -$15.5 million (2023), against an average of -$15.0 million.
• Across the five-year window, EBITDA plunged 264.58% in 2021 and increased 14.25% in 2025, its largest moves.
• Nautilus Biotechnology's EBITDA stood at -$16.9 million in 2021, then grew by 10.01% to -$15.2 million in 2022, then declined by 2.28% to -$15.5 million in 2023, then retreated by 23.82% to -$19.2 million in 2024, then increased by 14.25% to -$16.5 million in 2025.
• The last three EBITDA figures came in at -$16.5 million (Q1 2025), -$19.2 million (Q1 2024), and -$15.5 million (Q3 2023), per Business Quant data.